Compare Norfolk Southern Corporation (NSC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Norfolk Southern Corporation trades at $317.24 (market cap $71.20B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B). The key difference: Norfolk Southern Corporation is far larger — about 33.3× Recursion Pharmaceuticals Inc's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NSC | RXRX | |
|---|---|---|
Market Cap | $71.20B | $2.14B |
Volume | 555,248 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $352.98 | $6.79 |
52-Week Low | $278.19 | $2.84 |
Typical Hold Time | 33 Days | 22 Days |
Enterprise Value | $86.75B | $1.66B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $313.20, down 0.98% with bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.52 exceeding expectations by 6%. Valuation metrics include P/E of 26.72 and ROE of 16.97%, while the proposed Union Pacific merger progresses through regulatory review. Cash flow trends show operational strength with $4.36B from operations in 2025.
Outlook remains constructive with 43.75% analyst buy ratings and $361.86 consensus target offering 15.5% upside. Key risks include merger approval uncertainty and fuel cost pressures. The combination creates transcontinental railroad opportunities but faces STB regulatory hurdles. Earnings on October 22, 2026 will be critical for near-term direction.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
